Meiji Seika Kaisha, Ltd.

Meji Seika Kaisha Ltd.

Meui Seika Kaisha, Ltd.

Takashi Yaguchi

Naomi Sumida

Manabu Watanabe

Takayoshi Tamura

Naoki Mido

Toru Sasaki

Yuji Tabata

Shinji Miyadoh

Naoko Miike

Goh Tsujiuchi

Yasushi Kurata

Masahiro Hatsu

Ayako Someya

Nobuaki Kushida

Takashi Shomura

Akira Shimizu

Takeshi Murakami

Haruo Seto

Koji Yanai

Masaji Sezaki

Keiichi Ajito

Shuichi Gomi

Toshiaki Kono

Akitaka Nakane

Jinichiro Koga

Fumikazu Yokoyama

Osamu Hara

Kazuo Shin-Ya

Tatsuki Moriya

Yuko Baba

Masayuki Takagi

Tadaaki Okada

Tomoko Nishimura

Kouichirou Murashima

Masato Tani

Naoko Watanabe

Yuko Nakamura

Naotoshi Akai

Takao Shimizu

Eriko Tanaka

Takako Okuda

Masashi Niida

The present invention provides a protein having saponin-decomposing activity, more specifically a protein which can decompose a glycoside having soyasapogenol B as an aglycone to produce soyasapogenol B, a polynucleotide encoding such a protein, and a method of producing soyasapogenol B on a large scale using the same. A protein according to the present invention are concerned with (a), (b) or (c), namely (a) a protein comprising an amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 2, 4, and 6; (b) a protein that has at least 50% homology to the protein comprising the amino acid sequence of the sequence described in (a) and having saponin-decomposing activity; or (c) a protein comprising a modified amino acid sequence of the sequence described in (a) that has one or more amino acid residues deleted, substituted, inserted, or added and having saponin-decomposing activity.

Saponin-decomposing enzyme, gene thereof and large-scale production system for producing soyasapogenol B

Saponin-decomposing enzyme, gene thereof and large-scale production sytem for producing soyasapogenol B

This invention provides novel PF1270A substance, PF1270B substance and PF1270C substance represented by the following formula (1) or pharmaceutically acceptable salts thereof, a method for producing the same and a pharmaceutical composition which comprises at least one of the same as the active ingredient. Since a group of the PF1270 substances of the invention show high affinity for histamine Hreceptor, they are expected as novel histamine Hreceptor ligands useful as medicaments. 

Physiologically active substances PF1270A, B and C substances

Saponin-digesting enzymes, genes thereof and soyasapogenol B mass production system

It is an object of the present invention to provide enzymes that have high endoglucanase activity and yet exhibit high activity even under alkaline conditions, and genes encoding the same. The enzyme according to the invention has the following properties: a) exhibiting endoglucanase activity; and b) capable of completely removing fuzz from regenerated cellulose fabrics at a concentration of 1 mg of the protein/L or below. The enzyme of the invention having endoglucanase activity is a protein comprising the amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9 or 11; a modified protein thereof exhibiting endoglucanase activity; or a homologue of the protein or the modified protein.

Endoglucanases and cellulase preparations containing the same

An objective of the present invention is to provide a method of producing soyasapogenol B and to provide novel microorganisms. The present invention provides a method of producing soyasapogenol B comprising the steps of culturing microorganisms that belong to genusor genus, in a medium containing a glycoside having soyasapogenol B as an aglycone, and then collecting soyasapogenol B from the resulting culture.

Process for producing soyasapogenol B and novel microorganisms

A substance PF1191 having an inhibitory activity to kainic acid toxicity represented by the following formula (I) which is obtained by incubating a fungus belonging to the genus Eupenicillium and isolating the product thus produced from the culture by solvent extraction, adsorption column chromatography, gel filtration, etc.

Physiologically active substance PF1191 and process for producing the same

This invention provides novel physiologically active substances PF1092A, PF1092B and PF1092C, which can inhibit binding of progesterone to progesterone receptor. These substances were obtained by culturing a fungal microorganism belonging to the genus Penicillium using a medium containing ordinary nutrients for microorganisms and isolating the physiologically active substances PF1092A, PF1092B and PF1092C from the resulting culture mixture by means of solvent extraction, silica gel column chromatography, and the like. Molecular formulae of the novel physiologically active substances PF1092A, PF1092B and PF1092C are C.sub.17 H.sub.20 O.sub.5, C.sub.17 H.sub.20 O.sub.5 and C.sub.15 H.sub.18 O.sub.4, respectively.

Physiologically active substances PF1092A, PF1092B and PF1092C, process

Physiologically active substances PF1092A, PF1092B and PF1092C, and

A method of producing a 3-deacylated derivative of a 16-membered macrolide antibiotic using a microorganism belonging to the genus Phialophora or Preussia which comprises incubating said microorganism with a 16-membered macrolide antibiotic in a medium containing nutritional sources commonly used for incubating microorganisms, isolating a 3-deacylated derivative from the incubation medium, a microorganism to be used for the above method and a novel macrolide antibiotic.

Process for producing 3-deacylated derivative of 16-membered macrolide

A novel substance having anthelmintic activity, the PF 1022 substance, which is produced by cultivating a fungal strain capable of producing the substance and recovering the substance from the culture.

PF 1022 substance, method of treating helminthic parasitic infection and

Growing community of inventors

Odawara, Japan

Takashi Yaguchi